January 20, 2026
________________________________________________________________________________________________
Kindling Bio is proud to have been awarded 1st Prize in the BioSeed 2026 Showcase Competition hosted by OBN at County Hall, London on 19th January 2026.
At the event, our CEO and co-founder Aleck Jones presented Kindling Bio's rapid progress and vision for a fundamentally new approach to immunotherapy for both children and adults.
The showcase brought together 42 high-potential early-stage R&D companies, each pitching innovative opportunities across novel therapeutics, medical devices, and cutting-edge computational solutions, all with the potential for transformational impact and growth.
Kindling Bio is grateful to Thermo Fisher Scientific for the opportunity to showcase our progress and vision, and to everyone who supported us on the day. We look forward to continuing conversations with investors and partners who want to help accelerate our fundamentally different approach to immunotherapy to the clinic.
In the six months since Deep Science Ventures and InnovateUK backed our vision for a fundamentally different, scalable approach to cancer immunotherapy, we have:
- Delivered KND-001, our prototype viral platform.
- Filed our foundational patents.
- Won the Hack4Hope innovation forum, securing non-dilutive funds and a hugely valuable mentorship from the Paris- Saclay Cancer Cluster (PSCC).
- Won the BioSeed 2026 Showcase and Advanced Therapies 2025 Innovation Showcase.
- Established our labs at The London Cancer Hub, right at the centre of the UK’s most active ecosystem for oncology commercialisation.
Kindling Bio's Immune Flag platform has a rare dual potential to address the persistent neglect in new treatments for children with cancer and open a path to meaningful commercial returns in immune-cold adult tumours where conventional approaches continue to fall short.
About Kindling Bio
Kindling Bio is a biotechnology company developing paediatric-led, next-generation cancer gene therapies that reprogramme tumour biology and harness children’s immune responses to fight a wide range of tumours. The company is based at the London Cancer Hub.
About BioSeed
BioSeed is OBN's fast-paced pitching and investment event giving the opportunity for early-stage R&D companies to present to a room filled with Life Sciences Investors.rtant milestone for Kindling Bio as we continue to build a fundamentally different approach to cancer immunotherapy, designed around the unique biology and unmet needs of children.
